Active shortage
Enbrel 50 mg/mL injection
etanercept · 50 mg/mL injection
Enbrel
- Reported
- 3 March 2025
- Expected resolution
- 30 November 2025
- TGA reference
- TGA-MSI-2025-044
- Sponsor
- Pfizer Australia Pty Ltd
Reason for shortage
Pfizer biologic manufacturing capacity constraints. Rheumatoid arthritis and psoriasis patients must not stop biologic without specialist guidance.
What to do
- 1.Contact your pharmacist — Your pharmacist can check current stock levels and advise on nearby pharmacies that may have supply. They can also assist with early dispensing to avoid running out.
- 2.Ask your doctor about alternatives — Your GP or specialist can review whether a therapeutically equivalent alternative is appropriate for your situation. Never switch medicines without medical guidance.
- 3.Request early repeat if eligible — If you have active repeats, your pharmacist may dispense an early repeat to build a short buffer supply while the shortage persists.
- 4.Check TGA for updates — The TGA Medicine Shortage Information (MSI) database is updated regularly with expected resolution dates and approved substitutions.
- 5.Consider compounding if appropriate — For some medicines (particularly oral liquids or specific doses), a compounding pharmacist may be able to prepare an equivalent formulation.
Suggested alternatives
Same or related therapeutic class. Always discuss with your doctor or pharmacist before switching.
- Humira (adalimumab) — if available
- Benepali — etanercept biosimilar
- Discuss biologic switching with rheumatologist
Official resources
MedWatch is for informational purposes only and does not constitute medical advice. Never stop or change your medicines without consulting your doctor or pharmacist. In an emergency, call 000. Medication queries: National Medicines Line 1300 633 424.